Trials / Terminated
TerminatedNCT05389462
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 128 (actual)
- Sponsor
- ADC Therapeutics S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADCT-601 | Intravenous (IV) infusion |
| DRUG | Gemcitabine | Intravenous (IV) infusion |
Timeline
- Start date
- 2022-07-13
- Primary completion
- 2025-04-17
- Completion
- 2025-04-17
- First posted
- 2022-05-25
- Last updated
- 2025-05-22
Locations
14 sites across 4 countries: United States, France, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05389462. Inclusion in this directory is not an endorsement.